Amrubicin for non-small-cell lung cancer and small-cell lung cancer

Takayasu Kurata, Isamu Okamoto, Kenji Tamura, Masahiro Fukuoka

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Amrubicin is a totally synthetic anthracycline anticancer drug and a potent topoisomerase II inhibitor. Recently, amrubicin was approved in Japan for the treatment of small- and non-small-cell lung cancers (SCLC and NSCLC). Here, we review the efficacy and toxicities of amrubicin monotherapy and amrubicin in combination with cisplatin for extensive-disease SCLC (ED-SCLC), and of amrubicin monotherapy for advanced NSCLC, as observed in the clinical trials. Recommended dosage for previously untreated advanced NCSLC was 45 mg/m 2/day by intravenous administration for 3 days. Dose-limiting toxicities were leucopenia, thrombocytopenia, and gastrointestinal disturbance. Response rate was 27.9% for advanced NSCLC, and 75.8% for ED-SCLC with a median survival time (MST) of 11.7 months. Recommended dosage of amrubicin was 40 mg/m2/day in combination with cisplatin at 60 mg/m2/day, with MST of 13.6 months and 1-year survival rate of 56.1%. In sensitive or refractory relapsed SCLC, response rate was 52 and 50%, progression-free survival was 4.2 and 2.6 months, overall survival was 11.6 and 10.3 months, and 1-year survival rate was 46 and 40%, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer.

Original languageEnglish
Pages (from-to)499-504
Number of pages6
JournalInvestigational New Drugs
Volume25
Issue number5
DOIs
Publication statusPublished - Oct 1 2007
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Cisplatin
Clinical Trials
Topoisomerase II Inhibitors
Anthracyclines
Leukopenia
amrubicin
Thrombocytopenia
Intravenous Administration
Disease-Free Survival
Lung Neoplasms
Japan
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Amrubicin for non-small-cell lung cancer and small-cell lung cancer. / Kurata, Takayasu; Okamoto, Isamu; Tamura, Kenji; Fukuoka, Masahiro.

In: Investigational New Drugs, Vol. 25, No. 5, 01.10.2007, p. 499-504.

Research output: Contribution to journalReview article

Kurata, Takayasu ; Okamoto, Isamu ; Tamura, Kenji ; Fukuoka, Masahiro. / Amrubicin for non-small-cell lung cancer and small-cell lung cancer. In: Investigational New Drugs. 2007 ; Vol. 25, No. 5. pp. 499-504.
@article{1cd93d2d108348099310408acc2fe9ba,
title = "Amrubicin for non-small-cell lung cancer and small-cell lung cancer",
abstract = "Amrubicin is a totally synthetic anthracycline anticancer drug and a potent topoisomerase II inhibitor. Recently, amrubicin was approved in Japan for the treatment of small- and non-small-cell lung cancers (SCLC and NSCLC). Here, we review the efficacy and toxicities of amrubicin monotherapy and amrubicin in combination with cisplatin for extensive-disease SCLC (ED-SCLC), and of amrubicin monotherapy for advanced NSCLC, as observed in the clinical trials. Recommended dosage for previously untreated advanced NCSLC was 45 mg/m 2/day by intravenous administration for 3 days. Dose-limiting toxicities were leucopenia, thrombocytopenia, and gastrointestinal disturbance. Response rate was 27.9{\%} for advanced NSCLC, and 75.8{\%} for ED-SCLC with a median survival time (MST) of 11.7 months. Recommended dosage of amrubicin was 40 mg/m2/day in combination with cisplatin at 60 mg/m2/day, with MST of 13.6 months and 1-year survival rate of 56.1{\%}. In sensitive or refractory relapsed SCLC, response rate was 52 and 50{\%}, progression-free survival was 4.2 and 2.6 months, overall survival was 11.6 and 10.3 months, and 1-year survival rate was 46 and 40{\%}, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer.",
author = "Takayasu Kurata and Isamu Okamoto and Kenji Tamura and Masahiro Fukuoka",
year = "2007",
month = "10",
day = "1",
doi = "10.1007/s10637-007-9069-0",
language = "English",
volume = "25",
pages = "499--504",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - Amrubicin for non-small-cell lung cancer and small-cell lung cancer

AU - Kurata, Takayasu

AU - Okamoto, Isamu

AU - Tamura, Kenji

AU - Fukuoka, Masahiro

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Amrubicin is a totally synthetic anthracycline anticancer drug and a potent topoisomerase II inhibitor. Recently, amrubicin was approved in Japan for the treatment of small- and non-small-cell lung cancers (SCLC and NSCLC). Here, we review the efficacy and toxicities of amrubicin monotherapy and amrubicin in combination with cisplatin for extensive-disease SCLC (ED-SCLC), and of amrubicin monotherapy for advanced NSCLC, as observed in the clinical trials. Recommended dosage for previously untreated advanced NCSLC was 45 mg/m 2/day by intravenous administration for 3 days. Dose-limiting toxicities were leucopenia, thrombocytopenia, and gastrointestinal disturbance. Response rate was 27.9% for advanced NSCLC, and 75.8% for ED-SCLC with a median survival time (MST) of 11.7 months. Recommended dosage of amrubicin was 40 mg/m2/day in combination with cisplatin at 60 mg/m2/day, with MST of 13.6 months and 1-year survival rate of 56.1%. In sensitive or refractory relapsed SCLC, response rate was 52 and 50%, progression-free survival was 4.2 and 2.6 months, overall survival was 11.6 and 10.3 months, and 1-year survival rate was 46 and 40%, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer.

AB - Amrubicin is a totally synthetic anthracycline anticancer drug and a potent topoisomerase II inhibitor. Recently, amrubicin was approved in Japan for the treatment of small- and non-small-cell lung cancers (SCLC and NSCLC). Here, we review the efficacy and toxicities of amrubicin monotherapy and amrubicin in combination with cisplatin for extensive-disease SCLC (ED-SCLC), and of amrubicin monotherapy for advanced NSCLC, as observed in the clinical trials. Recommended dosage for previously untreated advanced NCSLC was 45 mg/m 2/day by intravenous administration for 3 days. Dose-limiting toxicities were leucopenia, thrombocytopenia, and gastrointestinal disturbance. Response rate was 27.9% for advanced NSCLC, and 75.8% for ED-SCLC with a median survival time (MST) of 11.7 months. Recommended dosage of amrubicin was 40 mg/m2/day in combination with cisplatin at 60 mg/m2/day, with MST of 13.6 months and 1-year survival rate of 56.1%. In sensitive or refractory relapsed SCLC, response rate was 52 and 50%, progression-free survival was 4.2 and 2.6 months, overall survival was 11.6 and 10.3 months, and 1-year survival rate was 46 and 40%, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=34547654536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547654536&partnerID=8YFLogxK

U2 - 10.1007/s10637-007-9069-0

DO - 10.1007/s10637-007-9069-0

M3 - Review article

VL - 25

SP - 499

EP - 504

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 5

ER -